Mechanism of Action: Glucagon Receptor Agonists

Drugs with Mechanism of Action: Glucagon Receptor Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zealand Pharma	ZEGALOGUE	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-001	Mar 22, 2021		RX	Yes	Yes
Zealand Pharma	ZEGALOGUE	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-001	Mar 22, 2021		RX	Yes	Yes			Y	Y
Zealand Pharma	ZEGALOGUE	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-001	Mar 22, 2021		RX	Yes	Yes
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes			Y	Y

Glucagon Receptor Agonists Market Analysis and Financial Projection

The glucagon receptor agonist (GRA) market is experiencing transformative growth, shaped by advancing therapeutic applications, patent strategies, and evolving competitive dynamics. Here's a detailed analysis:

---

Market Dynamics

Growth Drivers

• Rising Disease Prevalence: The global surge in type 2 diabetes and obesity is a primary driver. Over 537 million adults had diabetes in 2021, projected to rise to 783 million by 2045[6][12]. GRAs address these conditions by improving glycemic control and promoting weight loss[1][4].
• Pipeline Innovation: Over 20 pharma companies are developing next-generation GRAs, including oral formulations (e.g., Pfizer’s danuglipron) and multi-agonists targeting GLP-1, GIP, and glucagon receptors (e.g., Eli Lilly’s LY3437943)[4][11]. These innovations enhance efficacy and dosing convenience.
• Cardiometabolic Benefits: Drugs like Innovent’s mazdutide show superior glycemic control and improvements in blood pressure, liver enzymes, and lipid profiles, broadening their therapeutic appeal[1][16].

Market Projections

• The GLP-1 receptor agonist market was valued at $53.46 billion in 2024, expected to grow at a 17.46% CAGR through 2030[1]. The broader GLP-1 market could reach $90.6 billion by 2033[6], driven by Asia-Pacific’s expanding healthcare access[5][6].
• North America dominates (77.72% market share in 2024)[1], but Asia-Pacific is poised for rapid growth due to rising geriatric populations and affordability[6][12].

Challenges

• High Development Costs: Bringing a new GRA to market takes 10–15 years and costs over $2.6 billion, limiting small players[5][12].
• Patent Thickets: Manufacturers list median 19.5 patents per product, with 54% on delivery devices (e.g., injectors, oral devices), extending exclusivity to 18.3 years post-approval[2][3]. This delays generics, keeping prices elevated[2][3].

---

Patent Landscape

Strategic Patenting

• Device-Centric Claims: Over half of GRA patents focus on drug delivery mechanisms rather than active ingredients. For example, Biora Therapeutics holds patents for ingestible devices enabling 20%+ bioavailability for oral GRAs[14][18].
• Multi-Agonist Filings: Recent patents emphasize combination therapies (e.g., GLP-1/glucagon/GIP agonists) to enhance weight loss and metabolic benefits[7][11]. Eli Lilly’s triple agonist LY3437943 reduced HbA1c by 2.03% in trials[11].

Regulatory Exclusivity

• Brands augment patents with 2+ regulatory exclusivities (e.g., orphan drug status)[2]. For instance, Novo Nordisk’s semaglutide secured exclusivity extensions for pediatric obesity[20].

Litigation and Generic Barriers

• No generics have successfully challenged GRA patents[2]. Device patents create dense "thickets," reducing median patents from 20.5 to 6 if excluded[3], highlighting their role in blocking competition.

---

Competitive and Innovation Trends

Key Players

• Dominant Companies: Novo Nordisk, Eli Lilly, and AstraZeneca lead with blockbusters like Ozempic (semaglutide) and Mounjaro (tirzepatide)[6][16].
• Emerging Entrants: Viking Therapeutics and Innovent Biologics are advancing dual/triple agonists, while Carmot Therapeutics explores oral small molecules (e.g., CT-996)[1][4].

Innovation Focus

• Oral Delivery: Oral GRAs like Pfizer’s danuglipron and Rybelsus (semaglutide) aim to replace injections, improving patient adherence[8][9].
• Multi-Target Agonists: Drugs like Roche’s CT-388 (GLP-1/GIP agonist) and Lilly’s retatrutide (GLP-1/GIP/glucagon agonist) target >20% weight loss in trials[4][11].

---

Regional Insights

• North America: Accounts for 95% of the regional market (2023)[20], driven by high healthcare spending and obesity rates. The U.S. leads with approvals like Mounjaro for diabetes and obesity[17][20].
• Asia-Pacific: Expected to grow at 11.2% CAGR due to rising diabetes prevalence and improved healthcare infrastructure in China and India[6][12].

---

Future Outlook

• Patent Expiries: Key drugs face patent cliffs post-2030, likely opening doors for biosimilars[5][12].
• Affordable Access: Partnerships between innovators and generics (e.g., in India) could lower costs and expand reach[6][12].
• Next-Gen Therapies: Oral formulations, sustained-release injections, and gene therapies are under exploration to address unmet needs[7][21].

---

Key Takeaways

• GRAs are reshaping diabetes/obesity treatment with dual metabolic benefits.
• Patent strategies centered on delivery devices and multi-target agonists dominate the landscape.
• High costs and exclusivity barriers challenge affordability, but innovation and regional expansion offer growth avenues.

"The development of oral GLP-1RAs and multi-agonists represents a paradigm shift in metabolic disease management." — Industry Analyst, Grandview Research[1][16]

References

1. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
2. https://pubmed.ncbi.nlm.nih.gov/37505513/
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC10845039/
4. https://www.globenewswire.com/news-release/2024/07/23/2917497/0/en/GLP-Agonist-Clinical-Trial-Pipeline-Appears-Robust-With-20-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight.html
5. https://www.coherentmarketinsights.com/market-insight/glp-1-receptor-agonist-market-4632
6. https://www.alliedmarketresearch.com/glucagon-like-peptide-1-agonists-market-A324075
7. https://pubmed.ncbi.nlm.nih.gov/37870067/
8. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development
9. https://www.drugtopics.com/view/pfizer-advances-oral-glp-1-development-as-the-race-for-second-gen-obesity-therapies-continues
10. https://pubchem.ncbi.nlm.nih.gov/patent/US-8507428-B2
11. https://pubmed.ncbi.nlm.nih.gov/36354040/
12. https://www.coherentmarketinsights.com/market-insight/glp-1-receptor-agonist-market-4632
13. https://www.girolino.com/exploring-the-top-trends-in-the-glp-1-weight-loss-market-a-comprehensive-guide/
14. https://www.globenewswire.com/news-release/2022/09/13/2515031/0/en/Biora-Therapeutics-Announces-Issuance-of-Key-Patent-for-Oral-Delivery-of-GLP-1-Receptor-Agonists.html
15. https://en.wikipedia.org/wiki/Glucagon_receptor_agonist
16. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
17. https://www.datainsightsmarket.com/reports/north-america-glucagon-receptor-agonist-market-10758
18. https://www.globenewswire.com/news-release/2022/09/13/2515031/0/en/Biora-Therapeutics-Announces-Issuance-of-Key-Patent-for-Oral-Delivery-of-GLP-1-Receptor-Agonists.html
19. https://www.coherentmarketinsights.com/market-insight/glp-1-receptor-agonist-market-4632
20. https://www.mordorintelligence.com/industry-reports/north-america-glucagon-like-peptide-1-agonists-market
21. https://www.biorxiv.org/content/10.1101/2024.05.20.594997v1.full.pdf
22. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
23. https://www.girolino.com/exploring-the-top-trends-in-the-glp-1-weight-loss-market-a-comprehensive-guide/
24. https://patents.google.com/patent/US9764004B2/en
25. https://www.datainsightsmarket.com/reports/north-america-glucagon-receptor-agonist-market-10758
26. https://www.coherentmarketinsights.com/market-insight/glp-1-receptor-agonist-market-4632
27. https://www.girolino.com/exploring-the-top-trends-in-the-glp-1-weight-loss-market-a-comprehensive-guide/
28. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
29. https://www.mordorintelligence.com/industry-reports/north-america-glucagon-like-peptide-1-agonists-market
30. https://www.persistencemarketresearch.com/market-research/glp-1-receptor-agonist-market.asp
31. https://www.globenewswire.com/news-release/2022/09/13/2515031/0/en/Biora-Therapeutics-Announces-Issuance-of-Key-Patent-for-Oral-Delivery-of-GLP-1-Receptor-Agonists.html
32. https://www.coherentmarketinsights.com/market-insight/glp-1-receptor-agonist-market-4632
33. https://www.zealandpharma.com/media/juilfehy/zealand-pharma-march-2025.pdf
34. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
35. https://www.zealandpharma.com/media/juilfehy/zealand-pharma-january-2025.pdf
36. https://www.persistencemarketresearch.com/market-research/glp-1-receptor-agonist-market.asp
37. https://docs.publicnow.com/viewDoc.aspx?filename=126507%5CEXT%5CCD5957F4290EFEA6706EC3F9FD4950493635BC88_9A980799B5F4EC8AD44D180C7E4A895A83A617BE.PDF
38. https://www.insightaceanalytic.com/report/glp-1-agonists-market/2289
39. https://pubchem.ncbi.nlm.nih.gov/patent/US-8507428-B2
40. https://www.coherentmarketinsights.com/market-insight/glp-1-receptor-agonist-market-4632
41. https://www.globenewswire.com/news-release/2022/09/13/2515031/0/en/Biora-Therapeutics-Announces-Issuance-of-Key-Patent-for-Oral-Delivery-of-GLP-1-Receptor-Agonists.html
42. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
43. https://www.biorxiv.org/content/10.1101/2024.05.20.594997v1.full.pdf
44. https://www.persistencemarketresearch.com/market-research/glp-1-receptor-agonist-market.asp
45. https://www.sec.gov/Archives/edgar/data/2040807/000095017025044778/mtsr-20241231.htm
46. https://www.wjgnet.com/1948-5182/full/v16/i5/731.htm
47. https://www.datainsightsmarket.com/reports/north-america-glucagon-receptor-agonist-market-10758
48. https://pubchem.ncbi.nlm.nih.gov/patent/US-8507428-B2
49. https://www.persistencemarketresearch.com/market-research/glp-1-receptor-agonist-market.asp
50. https://www.girolino.com/exploring-the-top-trends-in-the-glp-1-weight-loss-market-a-comprehensive-guide/
51. https://www.globenewswire.com/news-release/2022/09/13/2515031/0/en/Biora-Therapeutics-Announces-Issuance-of-Key-Patent-for-Oral-Delivery-of-GLP-1-Receptor-Agonists.html
52. https://www.insightaceanalytic.com/report/glp-1-agonists-market/2289
53. https://visiblealpha.com/blog/visible-alpha-glp-1-drug-monitor-the-emerging-pipeline/
54. https://www.wjgnet.com/1948-5182/full/v16/i5/731.htm